

## Special Issue

# Clinical and Translational Research of Urological Cancer

### Message from the Guest Editors

It is our pleasure to invite you to collaborate on this Special Issue, 'Clinical and Translational Research of Urological Cancer'. The field of urological cancer is constantly evolving with new technologies, new therapeutic agents, and biomarkers with better perspectives for patients and urologists. The aim of this Issue is to give a panoramic view of the novelties and most recent, relevant evidence in the field of clinical and translational research of urological cancers, from the application of artificial intelligence to predict oncological outcomes to the new biomarkers and promising immunotherapy that have completely changed how urological cancers are managed. Original studies and reviews are more than welcome for this Issue to help increase our knowledge in the wide field of urological cancers.

### Guest Editors

Dr. Mauro Ragonese

Department of Urology, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, 00168 Rome, Italy

Dr. Luca Di Gianfrancesco

Department of Urology, Humanitas Gavazzeni, Bergamo, Italy

### Deadline for manuscript submissions

31 May 2026



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/240100](https://mdpi.com/si/240100)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)